莎普爱思：立他司特滴眼液III期临床试验完成首例受试者入组

Core Viewpoint - The company has initiated a Phase III clinical trial for its drug, Litasan Eye Drops, aimed at treating dry eye in the Chinese population, with the first subject enrolled on October 23, 2025 [1] Group 1: Clinical Trial Details - The trial is designed as a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of the drug in the target population [1] - As of the announcement date, the total research and development investment for this project has reached approximately 19.15 million yuan [1] Group 2: Development Risks - The drug development process from clinical trials to production is lengthy and involves multiple stages, which may lead to potential issues that could result in the termination of the research [1] - The company commits to providing timely updates on the progress of the trial [1]